Johnson & Johnson (JNJ) vs Pfizer Inc. (PFE)
Johnson & Johnson and Pfizer Inc. are both Drug Manufacturers General companies. Johnson & Johnson is the larger, with a market value of $652.8B against $161.7B — 4.0× the size. Johnson & Johnson trades at the lower P/E: 31.4× against 37.7×. Johnson & Johnson grew revenue faster over the last twelve months: 8.06% against −0.21%. Johnson & Johnson has the higher net margin (21.5% vs 6.80%) and the higher return on invested capital (15.5% vs 6.30%). Both pay a dividend; Pfizer Inc. yields more (6.18% vs 3.07%). Across the 23 metrics below, Johnson & Johnson leads on 13 and Pfizer Inc. on 10.
Valuation
Profitability
| Metric | JNJ | PFE | Drug Manufacturers General median |
|---|---|---|---|
| Gross margin | 67.91% | 73.18% | 72.77% |
| Operating margin | 27.69% | 21.70% | 18.90% |
| Net margin | 21.48% | 6.80% | 8.27% |
| Free cash flow margin | 23.20% | 17.25% | 17.25% |
| Return on equity | 25.74% | 4.97% | 6.97% |
| Return on assets | 10.67% | 2.13% | 2.76% |
| Return on invested capital | 15.51% | 6.30% | 6.30% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack